In patients with relapsing MS, the transition to cladribine from natalizumab is a safe and effective option that provides sustained disease stability.
A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...
MedPage Today on MSN2d
Trump Team Fires Alzheimer's Staff; Herpesvirus and Alzheimer's; MS Drug SwitchesAmong those fired in the recent spate of Trump administration cuts are staff members at the NIH's Center for Alzheimer's and ...
The main patents on Tysabri (natalizumab) expired in the US and Europe in February; although, various use patents claim protection until 2027 and are still in dispute. The green light from the FDA ...
and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014. That resulted in false claims for ...
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback